BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 37341156)

  • 1. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
    Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
    CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors.
    Guo X; Yang Y; Qian Z; Chang M; Zhao Y; Ma W; Wang Y; Xing B
    Cancer Lett; 2024 Jun; 592():216908. PubMed ID: 38677640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
    Luo P; Zhang L; Yang L; An Z; Tan H
    Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the tumour microenvironment in the angiogenesis of pituitary tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Dorward N; Grieve J; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    Endocrine; 2020 Dec; 70(3):593-606. PubMed ID: 32946040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive pituitary tumors (PitNETs).
    Nishioka H
    Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors.
    Yan N; Xie W; Wang D; Fang Q; Guo J; Chen Y; Li X; Gong L; Wang J; Guo W; Zhang X; Zhang Y; Gu J; Li C
    Genome Med; 2024 Jan; 16(1):2. PubMed ID: 38167466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
    Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
    Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the 2022 WHO Classification of Pituitary Tumors.
    Asa SL; Mete O; Perry A; Osamura RY
    Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
    Wang L; Wei C; Wang Y; Huang N; Zhang T; Dai Y; Xue L; Lin S; Wu ZB
    Front Endocrinol (Lausanne); 2023; 14():1149997. PubMed ID: 37534217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple tumorous lesions of the pituitary gland.
    Schöning JV; Flitsch J; Lüdecke DK; Fahlbusch R; Buchfelder M; Buslei R; Knappe UJ; Bergmann M; Schulz-Schaeffer WJ; Herms J; Glatzel M; Saeger W
    Hormones (Athens); 2022 Dec; 21(4):653-663. PubMed ID: 35947342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
    Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
    J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent Progress in Treatments of Pituitary Neuroendocrine Tumors(Pituitary Tumors)].
    Nishioka H
    No Shinkei Geka; 2024 May; 52(3):631-645. PubMed ID: 38783506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
    Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
    Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular biology of thyrotroph pituitary neuroendocrine tumors.
    Horiguchi K
    Endocr J; 2023 Feb; 70(2):135-139. PubMed ID: 36653153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiology, Genetics and Pathogenesis of Pituitary Neuroendocrine Tumors].
    Suzuki K; Tahara S
    No Shinkei Geka; 2023 Jul; 51(4):593-606. PubMed ID: 37491056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
    Luo M; Tang R; Wang H
    J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors.
    Lin S; Dai Y; Han C; Han T; Zhao L; Wu R; Liu J; Zhang B; Huang N; Liu Y; Lai S; Shi J; Wang Y; Lou M; Xie J; Cheng Y; Tang H; Yao H; Fang H; Zhang Y; Wu X; Shen L; Ye Y; Xue L; Wu ZB
    Genome Med; 2024 Apr; 16(1):60. PubMed ID: 38658971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.
    Asa SL
    Endocr Pathol; 2021 Jun; 32(2):222-227. PubMed ID: 33866514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.